The GenNext Board of Directors

Scot R Weinberger


Scot has over thirty years of industrial experience in pioneering and commercializing cutting-edge tools for life science research. Scot is a prolific inventor and holds 22 United States Patents for solutions in liquid chromatography, ultraviolet – visible spectrometry, capillary electrophoresis, time-of-flight mass spectrometry, matrix-assisted laser desorption/ionization, protein biochip technology, tandem mass spectrometry, and surface-tethered and free-solution label-free biosensors. He has authored over thirty scientific publications, 6 book chapters, and has over 2,000 citations in the areas of translational medicine, life science research, and technology development. As an entrepreneur, Scot has been in the founding teams of Linear Instruments, Linear Scientific, Biomolecular Separations, and Ciphergen Biosystems. More recently, he founded and launched Molecular Sensing and GenNext Technologies.

Dr. Joshua Sharp

Executive Director

Professor Sharp is a world-renowned and internationally recognized expert in HRPF. He has over twenty-one peer-reviewed articles and has presented numerous invited lectures on the subject of biopharmaceutical HRPF. Josh is also an Associate Professor of Pharmacology and Research Professor of the Research Institute of Pharmaceutical Sciences at the University of Mississippi.

Dr. John Grant

Non-Executive Director

Dr. Grant is the Founder and CEO of Lemnos Advisory, LLC, which provides insights into strategic topics and corporate development for operating companies, transaction advisors, investment banks, and venture investors. He also holds various director and advisor positions in technology-intensive startups and non-profit BODs, mentors and judges for venture accelerators, and invests with multiple angel groups.

Previously, Dr. Grant led global strategy and external business development in several 3M divisions within the Healthcare and Industrial Business Groups. He led and participated in 25 acquisitions, divestitures, and minority corporate venture investments. Earlier, he held managerial positions in product and technology development, quality management, strategic marketing, and business management.

Dr. Grant’s earned an MBA from the Carlson School of Management at the University of Minnesota and a PhD from Northwestern University. He is a member of the National Association of Corporate Directors and has earned the NACD Certified Director designation.

Martin Verhoef

Non-Executive Director

Martin Verhoef has over 30 years of experience in the life sciences and molecular diagnostics markets working in The Netherlands, Sweden, Germany and the US. His work in Fortune 500 companies as well as startups gives Martin an exceptional view on starting and growing companies.

Currently he is Interim CEO at IXRF Systems, a material sciences company. While at Inscopix, Martin was the Chief Commercial Officer and played a key role in the sale of the company to Bruker, Inc. Martin held VP positions in Marketing, Strategy and R&D at Molecular Devices, a Danaher operating company, before being promoted to VP of Innovation for the multibillion dollar Life Sciences Instrumentation Group. At Ciphergen, a proteomics company, Verhoef was Executive Vice President and President of the tools business and participated in the IPO. At PrimeraDx, Martin was CEO and raised a total of $48M in Series A and B.  He began his career at Agilent (then still Hewlett-Packard) as Marketing Manager and R&D Leader for the DNA micro-array program.

Martin holds a double BS degree in Clinical and Analytical Chemistry from the van ‘t Hoff Institute in Rotterdam, The Netherlands.

Request a custom HRPF webinar for your lab.

Discover the Benefits of HRPF

Accelerate biopharmaceutical and biosimilar development and protein conformational research.